(Q37801934)

23 August 2017

title

Development of cytarabine prodrugs and delivery systems for leukemia treatment (English)

1 reference

23 August 2017

1 reference

1 reference

Bhupender S. Chhikara

object named as

Bhupender S Chhikara

series ordinal

1

0 references

author name string

Keykavous Parang

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

22 October 2010

1 reference

Expert Opinion on Drug Delivery

23 August 2017

published in

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1399-1414

1 reference

Pharmacogenomics of pediatric acute lymphoblastic leukemia

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Emerging therapy for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Emerging drugs for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

The molecular pathology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Ligand-based targeted therapy for cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Induction therapy in acute myeloid leukemia: intensifying and targeting the approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Long term follow-up of combination chemotherapy-radiotherapy of stage III Hodgkin's disease. A cancer and acute leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Clinical applications of PET and PET/CT in pediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Current and emerging treatment options in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Recent advances in management of acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Modern approaches to treating chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Current and emerging therapies for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Prodrugs. Do they have advantages in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Carboxylic acid and phosphate ester derivatives of fluconazole: synthesis and antifungal activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-.beta.-D-arabinofuranosylcytosine conjugates of prednisolone and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

A Phospholipid Derivative of Cytosine Arabinoside and Its Conversion to Phosphatidylinositol by Animal Tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

The synthesis, characterization, and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Special feature of mixed phosphotriester derivatives of cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Nucleoside analogue delivery systems in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Liposomal cancer therapy: exploiting tumor characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Strategy for effective brain drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Cationic lipid-mediated nucleic acid delivery: beyond being cationic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Targeting anticancer drugs to tumor vasculature using cationic liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Lipophilic arabinofuranosyl cytosine derivatives in liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Emerging trends of nanomedicine--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Biodegradable polymeric nanoparticles based drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Niosomes in sustained and targeted drug delivery: some recent advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

Nanoparticular Drug Delivery System of Cytarabine Hydrochloride (CTH) for Improved Treatment of Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.527330

10.1517/17425247.2010.527330

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference